Author

kgreenwood

  • Kate Greenwood

    A New Cholesterol-Lowering Drug at What Price?

    By Kate Greenwood [Cross-posted at Health Reform Watch] This summer, the Food and Drug Administration (FDA) is expected to approve the first entries in a new class of drugs that lower patients’ low-density lipoprotein (LDL) cholesterol…

    A New Cholesterol-Lowering Drug at What Price?

    By

    kgreenwood

  • FDA

    Recommended Reading: New Empirical Analysis of False Claims Act Whistleblower Litigation

    By Kate Greenwood [Cross-posted at Health Reform Watch] Late last year, the Columbia Law Review published David Freeman Engstrom’s Private Enforcement’s Pathways: Lessons from Qui Tam Litigation, the fourth in a series of articles Professor Engstrom…

    Recommended Reading: New Empirical Analysis of False Claims Act Whistleblower Litigation

    By

    kgreenwood

  • Conflicts of Interest

    A “Money Blind” for Research into Maternal-Fetal Medication Risk?

    By Kate Greenwood [Cross-posted at Health Reform Watch] A week ago, the Food and Drug Administration announced the results of a review of the medical literature it conducted in response to “recent reports questioning the safety…

    A “Money Blind” for Research into Maternal-Fetal Medication Risk?

    By

    kgreenwood

  • Bioethics

    The Ethics of Using Placebo Controls in Ebola Clinical Trials

    [Blogger’s Note: I am very pleased to share this post by my colleague at Seton Hall Law, Carl Coleman. This post was cross-posted at Health Reform Watch.] By Carl H. Coleman With well over 5,000 global deaths from…

    The Ethics of Using Placebo Controls in Ebola Clinical Trials

    By

    kgreenwood

  • Kate Greenwood

    Addressing the Dearth of Data on Fetal Death: The Role of Hospitals*

    By Kate Greenwood [Cross-posted at Health Reform Watch] As I have blogged about before, including last year here, research and public health interventions aimed at preventing stillbirth are stymied by a dearth of data. In an…

    Addressing the Dearth of Data on Fetal Death: The Role of Hospitals*

    By

    kgreenwood

  • Kate Greenwood

    Doctors’ Decision-Making: Regression Proof?

    By Kate Greenwood[Cross-posted at Health Reform Watch] As I have blogged about before, last year, in Kaiser v. Pfizer, the First Circuit joined the handful of courts to have approved a causal chain of injury running…

    Doctors’ Decision-Making: Regression Proof?

    By

    kgreenwood

  • FDA

    What’s Next If the FDA Holds the Line on Social Media?

    By Kate Greenwood[Cross-posted at Health Reform Watch] Earlier this week, the Food and Drug Administration announced that it was reopening the comment periods for the two draft guidances on the use of social media to promote…

    What’s Next If the FDA Holds the Line on Social Media?

    By

    kgreenwood

  • Health Care Reform

    Discrimination on the Basis of Health Status in Health Insurance: “Market-Norm or Necessity”?

    By Kate Greenwood [Cross-posted at Health Reform Watch] In recent months, advocates have alleged that discrimination on the basis of health status in health insurance continues, notwithstanding the Affordable Care Act’s attempts to level the playing…

    Discrimination on the Basis of Health Status in Health Insurance: “Market-Norm or Necessity”?

    By

    kgreenwood

  • Health Care Finance

    An Autism Diagnosis: Still the Key to Unlocking Needed Services?

    By Kate Greenwood Cross-Posted at Health Reform Watch In a recent, very moving, post about her son’s diagnosis with autism at age eight, blogger Amy Storch writes: “I guess I should mention the obvious —…

    An Autism Diagnosis: Still the Key to Unlocking Needed Services?

    By

    kgreenwood